|
|
- 2019
Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patientsKeywords: blood-based biomarkers, Circulating free DNA (cfDNA), immunotherapy, neutrophil to lymphocyte ratio (NLR), non-small cell lung cancer (NSCLC) Abstract: We investigated whether early dynamic changes of circulating free (cfDNA) levels as well as the neutrophil to lymphocyte ratio (NLR) could predict nivolumab effectiveness in pretreated patients with advanced non-small cell lung cancer (NSCLC)
|
